Resveratrol: Cardiovascular Health, Longevity, Anti-Inflammatory & Metabolic Support — Evidence Review
⚡ 60-Second Summary
Resveratrol (3,5,4′-trihydroxystilbene) is a stilbenoid polyphenol found in red wine, grape skins, Japanese knotweed, and peanuts. It became famous after David Sinclair's 2003 Nature paper showing resveratrol extends lifespan in yeast by activating sirtuin 2 (Sir2). Subsequent research showed sirtuin activation by resveratrol in mammals and dose-dependent lifespan extension in lower organisms. Human RCTs have shown benefits for cardiovascular and metabolic markers but results are inconsistent.
Best-evidenced uses: Cardiovascular markers (LDL oxidation reduction, endothelial function improvement — multiple RCTs); anti-inflammatory effects (CRP and IL-6 reduction); insulin sensitivity (some RCTs in obese adults); SIRT1 activation and metabolic pathway effects (consistent at higher doses). Animal evidence for anti-cancer, neuroprotective, and longevity effects is robust; human evidence for longevity outcomes is limited.
Practical note: Standard resveratrol has poor oral bioavailability — it is rapidly conjugated by the gut wall and liver to glucuronide and sulfate conjugates. Trans-resveratrol is the biologically active form; cis-resveratrol is much less active. Pterostilbene is a methylated resveratrol analog with better bioavailability (80% vs. ~1% for plain resveratrol). Doses in human RCTs range from 75 mg to 5 g/day — with inconsistent dose-response relationships.
What is Resveratrol?
Resveratrol activates SIRT1 (a NAD+-dependent deacetylase) directly, which in turn activates PGC-1α (mitochondrial biogenesis), FOXO3a (stress resistance), and inhibits NF-κB (anti-inflammatory). SIRT1 activation mimics caloric restriction signaling — the same pathway that extends lifespan in CR animal models. Resveratrol also activates AMPK (independent of SIRT1), inhibits COX-1/COX-2 (anti-inflammatory), and inhibits aromatase (potential cancer-relevant).
Resveratrol became a cultural phenomenon after a 2006 Nature paper showed high-dose resveratrol prevented obesity-related mortality in mice. TIME magazine declared it the 'year's most exciting molecule' in 2006. David Sinclair (Harvard), Joseph Baur, and Johan Auwerx have been central researchers. Human trials began in the mid-2000s, with results more variable than the dramatic animal studies suggested. Despite mixed RCTs, resveratrol remains one of the most-researched longevity-associated natural compounds.
Evidence-based benefits
1. Cardiovascular and endothelial markers
Multiple RCTs show trans-resveratrol (75–500 mg/day) reduces LDL oxidation, improves endothelial function (FMD), and decreases inflammatory markers. Effects are most consistent in people with cardiovascular risk factors.
2. Insulin sensitivity and metabolic health
Several RCTs in obese adults or type 2 diabetics show resveratrol (500–2,000 mg/day) improves insulin sensitivity markers (HOMA-IR), mitochondrial gene expression in skeletal muscle, and reduces ectopic fat accumulation.
3. Anti-inflammatory effects
Meta-analyses confirm resveratrol significantly reduces CRP and other inflammatory markers, consistent with NF-κB inhibition at the cellular level.
Supplement forms compared
| Form | Typical dose / Bioavailability | Best for | Notes |
|---|---|---|---|
| Trans-resveratrol (pure active isomer) | 100–500 mg/day | Cardiovascular, anti-inflammatory, longevity | Most bioavailable form of resveratrol; must specify 'trans-' on label. |
| Micronized trans-resveratrol | 100–250 mg/day | Enhanced absorption through particle size reduction | Better dissolution than standard trans-resveratrol; used in some clinical trials. |
| Pterostilbene (methylated resveratrol) | 50–250 mg/day | Higher bioavailability (80% vs. ~1%) | Better absorbed, more methylated; different pharmacokinetics. See pterostilbene page. |
| Resveratrol + NMN/NR (combination) | Varies | Sirtuin activation with NAD+ precursor | Popular longevity stack; resveratrol activates sirtuins that require NAD+. |
How much should you take?
- Cardiovascular markers: 100–500 mg/day trans-resveratrol
- Metabolic/longevity: 250–1,000 mg/day
- Take with a fat-containing meal for best absorption
Resveratrol is generally well-tolerated at doses up to 1 g/day. At very high doses (3–5 g/day), GI effects and possible renal effects have been noted. The most important drug interaction is inhibition of CYP3A4 and P-glycoprotein — potentially affecting many medications.
Safety and side effects
Common side effects
- Mild GI upset, nausea, diarrhea at high doses (>1 g/day)
- Headache at high doses
- CYP3A4, CYP1A2 inhibition — significant drug interaction potential
- Possible estrogenic activity at high doses — use caution with hormone-sensitive conditions
Serious risks
Resveratrol at typical supplement doses (100–500 mg/day) has a good safety profile. At high doses (>1 g/day), GI effects and drug interactions become more clinically relevant. The possible estrogenic activity is debated — some studies show ER binding; others don't. Caution is warranted in people with estrogen-sensitive conditions.
Drug and nutrient interactions
- Warfarin — CYP2C9 inhibition and antiplatelet effects; monitor INR
- Chemotherapy (cyclophosphamide, doxorubicin) — complex interactions; some studies show antagonism; confirm with oncologist
- Immunosuppressants (cyclosporine) — CYP3A4 inhibition may raise drug levels
- Blood pressure medications — additive hypotensive effects
Check our free interaction checker for additional combinations.
Who might benefit — and who should use caution
| Most likely to benefit | Use with caution or seek guidance |
|---|---|
| People with cardiovascular risk factors seeking antioxidant and anti-inflammatory polyphenol support | People on multiple CYP-metabolized medications — significant interaction potential |
| Individuals interested in longevity-associated sirtuin pathway activation | People with hormone-sensitive cancers — possible estrogenic activity; confirm with oncologist |
| Those combining resveratrol with NMN/NR for comprehensive longevity supplementation | Pregnant or breastfeeding women — insufficient safety data |
| Adults with metabolic syndrome, insulin resistance, or elevated inflammatory markers |
Frequently asked questions
Does resveratrol work for longevity in humans?
Resveratrol extends lifespan in yeast, worms, fish, and mice. In humans, it activates SIRT1 and AMPK pathways, produces measurable improvements in cardiovascular and metabolic biomarkers, and shows anti-inflammatory effects. However, direct human longevity evidence (do people live longer) does not yet exist — those trials would take decades. The pathway activation and biomarker improvements are mechanistically meaningful but not the same as proven longevity extension.
Why are some resveratrol RCTs negative?
Multiple factors explain inconsistency: (1) poor bioavailability of plain resveratrol — many RCTs use doses where plasma levels are insufficient; (2) rapid metabolism to conjugates that may have different activity; (3) dose heterogeneity (75 mg to 5 g/day); (4) different health states of participants; (5) duration (some trials are too short for metabolic effects). Trials using trans-resveratrol at 250+ mg/day in people with risk factors show more consistent results.
Is pterostilbene better than resveratrol?
Pterostilbene (dimethoxy-resveratrol) has approximately 80% oral bioavailability compared to ~1% for plain resveratrol. It is more lipophilic, longer-acting, and better absorbed. Some studies suggest it may be more potent than resveratrol per mg absorbed. However, resveratrol has a much larger research database. Both have their place — pterostilbene is preferred for systemic bioavailability; resveratrol remains the reference standard for mechanism studies.
How does the French Paradox relate to resveratrol?
The French Paradox (low cardiovascular disease despite high saturated fat diet in France) was partly attributed to red wine consumption. Red wine contains resveratrol (~1 mg per glass) plus other polyphenols. However, the amounts of resveratrol in wine are far below therapeutic supplement doses — a glass of red wine provides ~1 mg; RCTs use 100–1,000 mg. The cardiovascular benefits of moderate wine consumption are more likely due to the whole polyphenol matrix and moderate alcohol than to resveratrol alone.
Should I combine resveratrol with NMN or NR?
This combination is mechanistically logical: resveratrol activates sirtuins (SIRT1 through direct allosteric binding), while NAD+ precursors (NMN, NR) provide the substrate sirtuins require for their deacetylase activity. Without adequate NAD+, SIRT1 cannot function optimally even if activated by resveratrol. This is the basis for the resveratrol + NAD+ precursor longevity stack popularized by David Sinclair's work. Whether the combination outperforms either alone in humans has not been definitively tested in RCTs.
Related ingredients
Trans-Resveratrol
The pure biologically active isomer — see for form-specific details.
NR (Nicotinamide Riboside)
NAD+ precursor that complements resveratrol's sirtuin activation mechanism.
NMN
The other major NAD+ precursor for the resveratrol-NAD+ longevity stack.
Disclaimer: This information is for educational purposes only and should not replace medical advice. Always consult a qualified healthcare provider before starting any supplement, especially if you have a medical condition, are pregnant, or take prescription medications. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.